Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register - PubMed
. 2006 Aug;54(8):2368-76.
doi: 10.1002/art.21978.
Affiliations
- PMID: 16868999
- DOI: 10.1002/art.21978
Free article
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register
W G Dixon et al. Arthritis Rheum. 2006 Aug.
Free article
Abstract
Objective: To determine whether the rate of serious infection is higher in anti-tumor necrosis factor (anti-TNF)-treated rheumatoid arthritis (RA) patients compared with RA patients treated with traditional disease-modifying antirheumatic drugs (DMARDs).
Methods: This was a national prospective observational study of 7,664 anti-TNF-treated and 1,354 DMARD-treated patients with severe RA from the British Society for Rheumatology Biologics Register. All serious infections, stratified by site and organism, were included in the analysis.
Results: Between December 2001 and September 2005, there were 525 serious infections in the anti-TNF-treated cohort and 56 in the comparison cohort (9,868 and 1,352 person-years of followup, respectively). The incidence rate ratio (IRR), adjusted for baseline risk, for the anti-TNF-treated cohort compared with the comparison cohort was 1.03 (95% confidence interval 0.68-1.57). However, the frequency of serious skin and soft tissue infections was increased in anti-TNF-treated patients, with an adjusted IRR of 4.28 (95% confidence interval 1.06-17.17). There was no difference in infection risk between the 3 main anti-TNF drugs. Nineteen serious bacterial intracellular infections occurred, exclusively in patients in the anti-TNF-treated cohort.
Conclusion: In patients with active RA, anti-TNF therapy was not associated with increased risk of overall serious infection compared with DMARD treatment, after adjustment for baseline risk. In contrast, the rate of serious skin and soft tissue infections was increased, suggesting an important physiologic role of TNF in host defense in the skin and soft tissues beyond that in other tissues.
Similar articles
-
Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A. Strangfeld A, et al. JAMA. 2009 Feb 18;301(7):737-44. doi: 10.1001/jama.2009.146. JAMA. 2009. PMID: 19224750
-
Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, Symmons DP; British Society for Rheumatology Biologics Register Control Centre Consortium; BSRBR. Harrison MJ, et al. Ann Rheum Dis. 2009 Feb;68(2):209-15. doi: 10.1136/ard.2007.087288. Epub 2008 Apr 2. Ann Rheum Dis. 2009. PMID: 18385277 Free PMC article.
-
Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M; REAL Study Group. Komano Y, et al. J Rheumatol. 2011 Jul;38(7):1258-64. doi: 10.3899/jrheum.101009. Epub 2011 Apr 15. J Rheumatol. 2011. PMID: 21498482
-
[New drugs and treatment strategies for rheumatoid arthritis].
Fantini F. Fantini F. Recenti Prog Med. 2003 Sep;94(9):361-79. Recenti Prog Med. 2003. PMID: 12942798 Review. Italian.
Cited by
-
Kim HW, Lee YJ, Ha YJ, Lee EB, Lee YJ, Kang EH. Kim HW, et al. Korean J Intern Med. 2024 Jul;39(4):668-679. doi: 10.3904/kjim.2023.276. Epub 2024 Feb 29. Korean J Intern Med. 2024. PMID: 38419335 Free PMC article.
-
Ritchlin CT, Stahle M, Poulin Y, Bagel J, Chakravarty SD, Kafka S, Srivastava B, Langholff W, Gottlieb AB. Ritchlin CT, et al. BMC Rheumatol. 2019 Nov 28;3:52. doi: 10.1186/s41927-019-0094-3. eCollection 2019. BMC Rheumatol. 2019. PMID: 31799498 Free PMC article.
-
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution.
Kuek A, Hazleman BL, Ostör AJ. Kuek A, et al. Postgrad Med J. 2007 Apr;83(978):251-60. doi: 10.1136/pgmj.2006.052688. Postgrad Med J. 2007. PMID: 17403952 Free PMC article. Review.
-
Cerda OL, de Los Angeles Correa M, Granel A, Marcos AI, Giraldo C, Rillo O, Schneeberger EE, Citera G. Cerda OL, et al. Eur J Rheumatol. 2019 Jan;6(1):19-22. doi: 10.5152/eurjrheum.2018.18096. Eur J Rheumatol. 2019. PMID: 30407165 Free PMC article.
-
The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection.
Atteno M, Costa L, Matarese A, Caso F, Del Puente A, Cantarini L, Bocchino ML, Sanduzzi A, Scarpa R. Atteno M, et al. Clin Rheumatol. 2014 Apr;33(4):543-7. doi: 10.1007/s10067-014-2536-z. Epub 2014 Feb 21. Clin Rheumatol. 2014. PMID: 24554385 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical